Welcome to AMYPAD!

We were a collaborative research initiative aiming to improve the understanding, diagnosis and management of Alzheimer’s disease through the utilisation of ß-amyloid PET imaging. AMYPAD was funded from October 2016 until September 2022.

The Amyloid imaging to prevent Alzheimer’s disease (AMYPAD) initiative aimed to:


→ About Us


→ Our papers


Homepage Image Neuraceq™ (left) and Vizamyl™ (right). Upper images: amyloid negative scans. Lower images: amyloid positive scans.
Latest News
AMYPAD at AD/PD 2023
AMYPAD at AD/PD 2023 01 Mar 2023 Several AMYPAD researchers will be presenting their respective work at the upcoming AD/PD™ Conference......
AMYPAD has been featured in the CORDIS
AMYPAD has been featured in the CORDIS "Results in Brief" section 21 Feb 2023 This article includes information on our key aims and the most important results that emanated from the AMYPAD project......
New AMYPAD paper highlighting European collaboration with global impact is out
New AMYPAD paper highlighting European collaboration with global impact is out 20 Jan 2023 In this new article, AMYPAD partners highlighted the important collaborations necessary to make a successful consortium......
"We would hope that the direct results of the project are useful about our thinking of when amyloid deposition starts and when it's clinically relevant. But what is even more important is that the consortium that we formed, started collaborating on things that go well beyond the initial goals of AMYPAD. And actually, we should further integrate AMYPAD, EPAD and all the European cohorts that are now collaborating and joining forces in analysis of PET/MRI scans, imaging, biomarker but also genetic data. It is something of great value and will contribute to the future of all samples, definitely in Europe and hopefully also globally. ” Frederik Barkhof
Frederik Barkhof

AMYPAD Project Coordinator and Professor of Neuroradiology at VU University Medical Centre, Amsterdam and at University College London.